Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

Gita Thanarajasingam, Lori M. Minasian, Frederic Baron, Franco Cavalli, R. Angelo De Claro, Amylou Dueck, Tarec C. El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S. Percy Ivy, Caron A. Jacobson, Armand Keating, Paul G. Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F. Little, Francois Xavier MahonMatthew J. Matasar, María Victoria Mateos, Kristen McCullough, Robert S. Miller, Mohamad Mohty, Philippe Moreau, Lindsay M. Morton, Sumimasa Nagai, Simon Rule, Jeff A Sloan, Pieter Sonneveld, Carrie A Thompson, Kyriaki Tzogani, Flora E. van Leeuwen, Galina Velikova, Diego Villa, John R. Wingard, Sophie Wintrich, John F. Seymour, Thomas Matthew Habermann

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.

Original languageEnglish (US)
JournalThe Lancet Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Hematologic Neoplasms
Neoplasms
Needs Assessment
Stem Cell Transplantation
B-Cell Lymphoma
Hematology
B-Cell Chronic Lymphocytic Leukemia
Disease Management
Multiple Myeloma
Chronic Disease
Survival Rate
Research Personnel
Clinical Trials
Survival
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Beyond maximum grade : modernising the assessment and reporting of adverse events in haematological malignancies. / Thanarajasingam, Gita; Minasian, Lori M.; Baron, Frederic; Cavalli, Franco; De Claro, R. Angelo; Dueck, Amylou; El-Galaly, Tarec C.; Everest, Neil; Geissler, Jan; Gisselbrecht, Christian; Gribben, John; Horowitz, Mary; Ivy, S. Percy; Jacobson, Caron A.; Keating, Armand; Kluetz, Paul G.; Krauss, Aviva; Kwong, Yok Lam; Little, Richard F.; Mahon, Francois Xavier; Matasar, Matthew J.; Mateos, María Victoria; McCullough, Kristen; Miller, Robert S.; Mohty, Mohamad; Moreau, Philippe; Morton, Lindsay M.; Nagai, Sumimasa; Rule, Simon; Sloan, Jeff A; Sonneveld, Pieter; Thompson, Carrie A; Tzogani, Kyriaki; van Leeuwen, Flora E.; Velikova, Galina; Villa, Diego; Wingard, John R.; Wintrich, Sophie; Seymour, John F.; Habermann, Thomas Matthew.

In: The Lancet Haematology, 01.01.2018.

Research output: Contribution to journalArticle

Thanarajasingam, G, Minasian, LM, Baron, F, Cavalli, F, De Claro, RA, Dueck, A, El-Galaly, TC, Everest, N, Geissler, J, Gisselbrecht, C, Gribben, J, Horowitz, M, Ivy, SP, Jacobson, CA, Keating, A, Kluetz, PG, Krauss, A, Kwong, YL, Little, RF, Mahon, FX, Matasar, MJ, Mateos, MV, McCullough, K, Miller, RS, Mohty, M, Moreau, P, Morton, LM, Nagai, S, Rule, S, Sloan, JA, Sonneveld, P, Thompson, CA, Tzogani, K, van Leeuwen, FE, Velikova, G, Villa, D, Wingard, JR, Wintrich, S, Seymour, JF & Habermann, TM 2018, 'Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies', The Lancet Haematology. https://doi.org/10.1016/S2352-3026(18)30051-6
Thanarajasingam, Gita ; Minasian, Lori M. ; Baron, Frederic ; Cavalli, Franco ; De Claro, R. Angelo ; Dueck, Amylou ; El-Galaly, Tarec C. ; Everest, Neil ; Geissler, Jan ; Gisselbrecht, Christian ; Gribben, John ; Horowitz, Mary ; Ivy, S. Percy ; Jacobson, Caron A. ; Keating, Armand ; Kluetz, Paul G. ; Krauss, Aviva ; Kwong, Yok Lam ; Little, Richard F. ; Mahon, Francois Xavier ; Matasar, Matthew J. ; Mateos, María Victoria ; McCullough, Kristen ; Miller, Robert S. ; Mohty, Mohamad ; Moreau, Philippe ; Morton, Lindsay M. ; Nagai, Sumimasa ; Rule, Simon ; Sloan, Jeff A ; Sonneveld, Pieter ; Thompson, Carrie A ; Tzogani, Kyriaki ; van Leeuwen, Flora E. ; Velikova, Galina ; Villa, Diego ; Wingard, John R. ; Wintrich, Sophie ; Seymour, John F. ; Habermann, Thomas Matthew. / Beyond maximum grade : modernising the assessment and reporting of adverse events in haematological malignancies. In: The Lancet Haematology. 2018.
@article{e084c49d140748bf806ef3bd3416079a,
title = "Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies",
abstract = "Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.",
author = "Gita Thanarajasingam and Minasian, {Lori M.} and Frederic Baron and Franco Cavalli and {De Claro}, {R. Angelo} and Amylou Dueck and El-Galaly, {Tarec C.} and Neil Everest and Jan Geissler and Christian Gisselbrecht and John Gribben and Mary Horowitz and Ivy, {S. Percy} and Jacobson, {Caron A.} and Armand Keating and Kluetz, {Paul G.} and Aviva Krauss and Kwong, {Yok Lam} and Little, {Richard F.} and Mahon, {Francois Xavier} and Matasar, {Matthew J.} and Mateos, {Mar{\'i}a Victoria} and Kristen McCullough and Miller, {Robert S.} and Mohamad Mohty and Philippe Moreau and Morton, {Lindsay M.} and Sumimasa Nagai and Simon Rule and Sloan, {Jeff A} and Pieter Sonneveld and Thompson, {Carrie A} and Kyriaki Tzogani and {van Leeuwen}, {Flora E.} and Galina Velikova and Diego Villa and Wingard, {John R.} and Sophie Wintrich and Seymour, {John F.} and Habermann, {Thomas Matthew}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S2352-3026(18)30051-6",
language = "English (US)",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Beyond maximum grade

T2 - modernising the assessment and reporting of adverse events in haematological malignancies

AU - Thanarajasingam, Gita

AU - Minasian, Lori M.

AU - Baron, Frederic

AU - Cavalli, Franco

AU - De Claro, R. Angelo

AU - Dueck, Amylou

AU - El-Galaly, Tarec C.

AU - Everest, Neil

AU - Geissler, Jan

AU - Gisselbrecht, Christian

AU - Gribben, John

AU - Horowitz, Mary

AU - Ivy, S. Percy

AU - Jacobson, Caron A.

AU - Keating, Armand

AU - Kluetz, Paul G.

AU - Krauss, Aviva

AU - Kwong, Yok Lam

AU - Little, Richard F.

AU - Mahon, Francois Xavier

AU - Matasar, Matthew J.

AU - Mateos, María Victoria

AU - McCullough, Kristen

AU - Miller, Robert S.

AU - Mohty, Mohamad

AU - Moreau, Philippe

AU - Morton, Lindsay M.

AU - Nagai, Sumimasa

AU - Rule, Simon

AU - Sloan, Jeff A

AU - Sonneveld, Pieter

AU - Thompson, Carrie A

AU - Tzogani, Kyriaki

AU - van Leeuwen, Flora E.

AU - Velikova, Galina

AU - Villa, Diego

AU - Wingard, John R.

AU - Wintrich, Sophie

AU - Seymour, John F.

AU - Habermann, Thomas Matthew

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.

AB - Tremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have increased, nowhere has progress been more impactful than in the management of typically incurable forms of haematological cancer. Population-based data have shown that 5-year survival for patients with chronic myelogenous and chronic lymphocytic leukaemia, indolent B-cell lymphomas, and multiple myeloma has improved markedly. This improvement is a result of substantial changes in disease management strategies in these malignancies. Several haematological malignancies are now chronic diseases that are treated with continuously administered therapies that have unique side-effects over time. In this Commission, an international panel of clinicians, clinical investigators, methodologists, regulators, and patient advocates representing a broad range of academic and clinical cancer expertise examine adverse events in haematological malignancies. The issues pertaining to assessment of adverse events examined here are relevant to a range of malignancies and have been, to date, underexplored in the context of haematology. The aim of this Commission is to improve toxicity assessment in clinical trials in haematological malignancies by critically examining the current process of adverse event assessment, highlighting the need to incorporate patient-reported outcomes, addressing issues unique to stem-cell transplantation and survivorship, appraising challenges in regulatory approval, and evaluating toxicity in real-world patients. We have identified a range of priority issues in these areas and defined potential solutions to challenges associated with adverse event assessment in the current treatment landscape of haematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85048309335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048309335&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(18)30051-6

DO - 10.1016/S2352-3026(18)30051-6

M3 - Article

C2 - 29907552

AN - SCOPUS:85048309335

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

ER -